Teva bails from OncoGenex custirsen deal; paying $27m

Teva will start 2015 by returning the rights to OncoGenex for custirsen, which failed a Phase III metastatic castrate-resistant prostate cancer study this past spring.

Teva is paying OncoGenex $27m to end the collaboration, which was formed in 2009.